25yr old presented as DKA C-Peptide - 0 ANTI GAD negative
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
DKA C-peptide negative anti-GAD negative diabetes classification
Reading File
Finding Sources
Searching PubMed
ketosis prone diabetes type 1B GAD negative
Finding Sources
Finding Sources
Searching PubMed
ketosis prone diabetes antibody negative C-peptide
Reading File
Finding Sources
This is a clinically important and nuanced case. Here is a structured analysis:
Clinical Interpretation: DKA + C-Peptide = 0 + Anti-GAD Negative
The Puzzle
| Finding | Implication |
|---|---|
| DKA at age 25 | Absolute insulin deficiency driving ketogenesis |
| C-peptide = 0 | No residual beta cell function — complete insulin deficiency |
| Anti-GAD negative | No detectable autoimmune beta cell destruction (at this timepoint) |
The combination creates a diagnostic dilemma: the patient behaves like classic Type 1A (absolute insulin deficiency causing DKA) but lacks the cardinal autoimmune marker.
Differential Diagnosis
1. Type 1B Diabetes (Idiopathic Type 1)
The most important consideration here. Type 1 diabetes is subdivided into:
- Type 1A — immune-mediated; GAD, IA-2, ZnT8, IAA antibodies typically present
- Type 1B — idiopathic; no autoimmune markers, yet still has selective beta cell destruction and absolute insulin deficiency
"Type 1 diabetes is further subdivided into immune-mediated (type 1a) and idiopathic causes (type 1b)… The hallmark is selective beta cell destruction and severe or absolute insulin deficiency." — Katzung's Basic and Clinical Pharmacology, 16th Ed.
Type 1B is more prevalent in people of African and Asian descent and can present at any age with DKA.
2. Ketosis-Prone Diabetes (KPD) — "Flatbush Diabetes" / A−β+ subtype
A distinct syndrome, particularly common in African, African-American, Hispanic, and South Asian individuals:
- Presents with DKA (like this patient)
- Anti-GAD negative (A−)
- C-peptide may be near-zero at presentation due to glucose toxicity suppressing beta cell function
- Critical distinction: C-peptide can recover after resolution of ketoacidosis and glucose normalization
- These patients often go into remission and may not require insulin long-term
The Balasubramanyam classification (A/β system) is key here:
| Subtype | Antibodies | β-cell function | Course |
|---|---|---|---|
| A+β+ | Present | Preserved | Classic T1DM |
| A+β− | Present | Absent | Classic T1DM |
| A−β+ | Absent | Recovers | KPD — may not need insulin permanently |
| A−β− | Absent | Absent | KPD / Type 1B — needs permanent insulin |
This patient is currently presenting as A−β− (antibody-negative, C-peptide-negative at presentation).
3. LADA (Latent Autoimmune Diabetes in Adults)
Less likely here — LADA patients typically:
- Have detectable autoantibodies (especially anti-GAD)
- Rarely present with florid DKA initially
- Have preserved partial C-peptide
4. Other Antibodies Not Tested
Anti-GAD alone has ~70-80% sensitivity for Type 1A. Additional antibodies should be checked:
- Anti-IA-2 (islet tyrosine phosphatase)
- Anti-ZnT8 (zinc transporter 8)
- Islet cell antibodies (ICA)
- Insulin autoantibodies (IAA) — if not yet started on insulin
A negative panel (all 4) would more convincingly exclude autoimmune T1DM.
Key Management Consideration: C-Peptide Recovery Test
Since KPD (A−β− at presentation) can recover beta-cell function:
- Recheck C-peptide after 4–8 weeks of euglycemia on insulin therapy
- If C-peptide recovers → consistent with A−β+ KPD → may attempt insulin weaning
- If C-peptide remains zero → consistent with Type 1B / A−β− KPD → permanent insulin required
Immediate Management
Regardless of classification, acute DKA management is the same:
- IV fluid resuscitation (0.9% NaCl initially)
- Insulin infusion (0.1 unit/kg/hr after potassium >3.5 mEq/L)
- Potassium replacement
- Monitor glucose, electrolytes, pH, anion gap hourly
- Transition to subcutaneous insulin once anion gap closed and patient tolerating oral intake
Summary
This patient most likely has either Type 1B (idiopathic) diabetes or Ketosis-Prone Diabetes (A−β− subtype). The zero C-peptide at DKA presentation does not rule out KPD because glucose toxicity can transiently suppress beta cell function. The anti-GAD negativity does not exclude Type 1 diabetes — full autoantibody panel (IA-2, ZnT8, ICA, IAA) is warranted.
The single most important next step diagnostically is to recheck C-peptide 4–8 weeks after euglycemia is restored — recovery would change the long-term management significantly.
Recent literature (PMID 41214251, Diabetologia 2026) confirms that autoantibody-negative Type 1 diabetes is a clinically distinct entity with different immunogenetic characteristics but similar metabolic severity.
This is a shared conversation. Sign in to Orris to start your own chat.